We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Abiraterone Tx Boosts Survival in Prostate Cancer
Abiraterone Tx Boosts Survival in Prostate Cancer
September 18, 2012
Final results of a phase III trial confirm that treatment with abiraterone prolongs overall survival in metastatic castration-resistant prostate cancer that has progressed after docetaxel therapy. MedPage Today
